Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia
نویسندگان
چکیده
منابع مشابه
Pericarditis during interferon-alpha therapy in chronic myelogenous leukemia.
(IFN-␣) can induce molecular remission in chronic myelogeneous leukemia (CML). 1 This may indicate that it could be opportune to prolong IFN treatment for a long time; however, albeit rarely, this therapeutic strategy can produce unusual complications. 2 In this regard, we believe it useful to report the development of pericardial effusion in a 28-year-old Ph-positive CML patient during therapy...
متن کاملJuvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha 2B.
Juvenile chronic myelogenous leukemia (JCML) is a rare malignant hematopoietic disorder representing only 2% of all childhood leukemias. The disease has a rapid course and has a median survival of less than 10 months when untreated or undertreated(l,2). Patients are often difficult to diagnose because of their clinical heterogeneity. A remarkable feature is increased synthesis of HbF and excess...
متن کاملTherapy of Chronic Myelogenous Leukemia With Recombinant Interferon-’y
Recently. we reported that recombinant interferon-a (rIFN-a) can induce hematologic remissions and cytogenetic improvement in newly diagnosed Philadelphia (Ph)positive chronic myelogenous leukemia (CML) patients. Although IFN-”y is a structurally distinct molecule. this agent suppresses in vitro hematopoietic progenitor cells in a fashion similar to that of IFN-a. Therefore. we initiated a stud...
متن کاملClinical investigation of human alpha interferon in chronic myelogenous leukemia.
Fifty-one patients with previously untreated or minimally treated chronic myelogenous leukemia in chronic phase received human alpha interferon 3 to 9 X 10(6) units intramuscularly (IM) daily until complete hematologic remission, then at doses ranging from 3 X 10(6) units every other day to 9 X 10(6) units daily. Forty-one (80%) patients achieved a hematologic response, 36 (71%) of them attaini...
متن کاملInterferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trial.
We read with interest the report of Hehlmann et all in which 133 patients were randomized to interferon-a (IFN-a) therapy (5 X lo6 U/m2/d). The incidence of complete hematologic response. (CHR) was 31% and of complete cytogenetic response was 7%. Their median survival was 5.5 years, which was superior to that of 186 patients treated with busulfan (median survival, 3.8 years; P = .008), but simi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2002
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.10090